A landmark pharmaceutical partnership between the UK and the USA has been finalised, promising significant benefits for NHS patients and British businesses. This agreement ensures improved access to life-changing treatments for patients and secures tariff-free exports for the UK’s pharmaceutical industry, fostering economic growth and safeguarding skilled jobs.
Key takeaways
- NHS patients to gain faster access to innovative medicines.
- UK becomes the first nation with a commitment to 0% tariffs on pharmaceutical exports to the US.
- Boost for the UK’s life sciences sector, encouraging investment and job creation.
- Updated NICE evaluation threshold to allow more treatments to be approved.
Accelerated access to new medicines
The agreement aims to accelerate the availability of new and innovative treatments for NHS patients. Pharmaceutical companies are now incentivised to launch groundbreaking medicines, including cancer therapies and treatments for rare diseases, in the UK sooner. This means patients will no longer face lengthy waits after a drug becomes available elsewhere.
Economic benefits for British businesses
This partnership is set to significantly benefit the UK’s pharmaceutical industry, which is a major contributor to the economy and a significant employer. UK pharmaceutical exports to the US, valued at billions of pounds annually, will be tariff-free for at least three years. This provides crucial certainty for businesses, encouraging further investment in research, development, and manufacturing within the UK. The medtech sector also stands to gain from preferential terms on exports to the US, with no additional tariffs for at least three years, further strengthening the UK’s position as a leader in health innovation.
Updated NICE evaluation criteria
As part of the changes, the National Institute for Health and Care Excellence (NICE) has updated its methodology for evaluating medicines. The cost-effectiveness threshold, which had not been revised in over two decades, has been adjusted to reflect changes in the economic and healthcare landscape. This update is expected to allow more treatments that offer significant health improvements, but might have previously been deemed too costly, to be approved for NHS use. Already, two new cancer medicines have been recommended under the new threshold, providing immediate access for patients with conditions like brain cancer and a rare form of stomach cancer.
Driving innovation and investment
A new Joint Taskforce has been launched, comprising government, industry leaders, NHS England, NICE, and patient groups. This taskforce will focus on accelerating innovation within the UK’s commercial environment for medicines, with the goal of making the UK a leading global life sciences economy. The government has also committed to doubling spending on innovative medicines as a proportion of GDP over the next decade, signalling a strong long-term commitment to the sector and attracting global investment.
